Mycobacterium tuberculosis (M.tb) has potent immunostimulatory properties and has been used in 43 adjuvant preparations to improve vaccine responses in animals. This study shows that natural M.tb 44 infection in humans is associated with increased antibody and B cell recall responses to heterologous 45 pathogens. This data suggests a potential role for M.tb antigens in immunotherapies designed to 46 maintain antibody immunity to diverse infections. 47
Antibody avidity was investigated using surface plasmon resonance and B cell ELISPOT assays were 31 used to measure plasmablast and memory B cell responses (MBC) in APTB cases and healthy donor 32 controls. APTB was associated with higher levels of antibodies to tetanus toxoid (TT), diphtheria 33 toxoid, respiratory syncytial virus, measles virus and Kaposi's sarcoma herpesvirus, compared to 34 uninfected controls. Vaccination with BCG did not alter levels of antibodies against heterologous 35 pathogens. TT-specific antibody avidity was increased in APTB and the ratio of TT-specific 36 plasmablasts to MBCs in the APTB cases was 7:1. M.tb infection boosts serological memory to 37 heterologous pathogens in human subjects and this process may be driven by polyclonal activation 38 of memory B cells. 39 48 1.0 Introduction 49 The Mycobacterium tuberculosis complex (MTBC) is made up of several mycobacterial species that cause 50 tuberculosis (TB), a disease that affects millions of people worldwide. There were 10 million cases of 51 TB disease in 2017, 1.6 million deaths, and a quarter of the world's population is estimated to be 52 infected (1). Despite the seriousness of the disease caused by MTBC, some of these pathogens have 53 use as immunotherapies due to their potent immunostimulatory properties. The most important 54 member of the MTBC, Mycobacterium tuberculosis (M.tb), is well known for its adjuvant properties. It is 55 a constituent of Freund's complete adjuvant and is thought to improve vaccine responses through 56 its stimulatory effect on antigen presenting cells such as dendritic cells and macrophages (2). 57
Mycobacterium bovis Bacille Calmette Guerin (BCG) has been used to treat bladder cancer for over 30 58 years (3). The exact mechanism of action has not been fully elucidated, but the common hypothesis 59 is that BCG draws innate immune cells into the bladder and primes them to attack cancer cells (4). 60
Increasing evidence has been put forward supporting a potential role for BCG in the protection of 61 infants from diseases caused by heterologous pathogens. Early studies in Guinea Bissau showed a 62 decrease in deaths from infectious diseases among low birth weight infants who were given BCG 63 vaccine at birth (5, 6) . These effects are thought to be as a result of improved function of innate 64 immune cells brought about by cellular epigenetic modifications induced by BCG (9) . There may 65 also be non-specific effects on the adaptive immune system. Ota et al. (7) described higher hepatitis 66 B virus-specific antibody responses in infants who were given BCG in addition to hepatitis B 67 vaccination at birth, compared to those who were only vaccinated with hepatitis B. A more recent 68 study by Ritz and colleagues (8) reported that the level of antibodies elicited by pneumococcal 69 vaccination of infants at two, four and six months of age were higher in those infants who were 70
given BCG at birth compared to those who were not. BCG may therefore improve immune 71 responses to vaccines given at the same time as BCG or those given following BCG vaccination, in a 72 non-specific manner. 73
The studies highlighted above describe the effect of mycobacteria on responses to concurrently 74 administered vaccine antigens or those given after vaccination with mycobacterial preparations. 75
However, studies in the past have shown that purified protein derivative (PPD) from M.tb can 76 stimulate secretion of antibodies against measles, rubella and herpes simplex viruses from human 77 peripheral blood mononuclear cells (PBMCs) in vitro (10). This finding suggests that M.tb may be 78 able to enhance antibody/B-cell memory responses generated from previous exposure to unrelated 79 pathogen-derived antigens. The exact immunological mechanism underlying this observation is not 80 yet known; however, it is possible that Mycobacterium antigens could non-specifically activate 81 pathogen-specific memory B cells (MBCs), resulting in the expansion of antibody-secreting cells and 82 a subsequent rise in antibody levels. Human MBCs are prone to activation by polyclonal stimulation; 83 studies by Bernasconi and colleagues (11) have shown that stimulation of these cells by bacterial 84 CpG (cytosine-phosphate-guanine) DNA or by T cell cytokines can lead to their proliferation and 85 expansion into antibody-secreting cells. However, this hypothesis has not been investigated in regard 86
to Mycobacterium tuberculosis exposure. Furthermore, it is not known whether natural M.tb infection 87 has the same non-specific stimulatory effect on antibody responses to recall antigens from 88 heterologous pathogens. We also do not know whether recent vaccination with the related species, 89 M. bovis BCG has a similar effect on serological recall responses to unrelated antigens. 90
This study characterised antibody responses to heterologous pathogen recall antigens in uninfected 91 controls, individuals with a latent TB infection (LTBI) or active pulmonary TB cases (APTB) cases 92 participating in a TB household contact study in Uganda, as well as adolescent recipients of the 93 BCG vaccine and their age-matched naïve controls from the United Kingdom. Additionally, 94 polyclonal activation of MBCs was explored as a possible mechanism by studying frequencies of 95 tetanus toxoid (TT)-specific plasmablasts and MBCs in the APTB cases and healthy donors. 96
Results

97
Demographics
98
The characteristics of the Ugandan TB household contact study participants have been described 99 previously (12) and in Supplementary Table 1 . In summary, APTB cases and individuals with LTBI 100 were older than the uninfected individuals and there was a larger proportion of males in the APTB 101 group in comparison to the other two groups. There were also more HIV positive individuals and a 102 larger proportion of people of low socioeconomic class among the APTB group. 103
The adolescents studied in the UK were all aged between 12 and 13 years, had no previous BCG 104 scar and were tuberculin skin test negative (13). 105 2.2 M.tb infection state is associated with increased antibody 106 responses to unrelated pathogens 107 Antibody responses were compared across groups of uninfected individuals, individuals with LTBI 108 and APTB cases from Uganda to determine the impact of M.tb infection state on antibody responses 109 to heterologous pathogens. Since we were interested in recall responses, we studied antibodies 110 against antigens contained in childhood vaccines, such as tetanus toxoid (TT), diphtheria toxoid 111 (DT) and measles virus (MV). We also measured antibodies specific for infections that our 112 participants may have had a high chance of encountering in childhood in this setting. These included 113 respiratory syncytial virus (RSV) (14), adenovirus (15), Kaposi's sarcoma herpes virus (KSHV) (16), 114 cytomegalovirus (CMV) (17) and Epstein Barr virus (EBV) (18). M.tb purified protein derivative 115 (PPD) was included as a positive control indicative of mycobacterial exposure. Initial crude analyses 116 revealed evidence of differences in the levels of antibodies specific to PPD, DT, RSV, MV, KSHV 117 ORF73, KSHV 8.1 and CMV antigens across the groups (Fig. 1 ). There were also differences in 118 total IgG antibody concentrations ( Supplementary Fig. 1 ). There was no evidence of differences in 119 EBV and adenovirus-specific antibodies across the groups ( Supplementary Fig. 1) . 120
In the final analyses, associations between M.tb infection status and antibody responses were 121 determined by means of linear regression analysis using the uninfected controls as the baseline 122 comparison group while adjusting for the effects of age, gender, HIV infection status and 123 socioeconomic status. APTB was associated with higher levels of anti-PPD, anti-TT, anti-DT, anti-124 RSV, anti-MV and anti-KSHV 8.1 compared to the uninfected individuals but there was no 125 association between M.tb infection status and anti-KSHV ORF73 or anti-CMV antibodies (Table 1) . 126
Total IgG levels were raised in the APTB cases compared to the uninfected controls (Supplementary 127 Table 2 ). There were no associations between M.tb infection status and anti-EBV or anti-adenovirus 128 antibodies, in agreement with findings from the crude analyses ( Supplementary Table 2 ). LTBI was 129 associated with higher anti-DT antibodies and weakly associated with higher anti-TT antibodies. 130 LTBI was also marginally associated with higher anti-PPD antibodies. Taken together, these results 131
show that M.tb infection, particularly APTB, is associated with higher levels of antibody responses to 132 several heterologous pathogen recall antigens. 133 134 
BCG vaccination is not associated with increased
144 antibody responses to unrelated pathogens 145 Next, we determined whether recent vaccination with the related species, Mycobacterium bovis BCG, 146 was also associated with elevated antibody responses to unrelated recall pathogen antigens. Antibody 147 responses were evaluated in a UK cohort of adolescents comprising a test group of 12 individuals 148 who received BCG, and 13 age-matched BCG naïve controls, and the two compared at timepoints 149 before and 3 weeks after vaccination of the test group. This cohort allowed us to compare BCG 150 vaccinated individuals to a BCG naïve group, which we could not do in the Ugandan participants 151 because BCG is routinely given to infants as part of the Uganda National Expanded Programme on 152
Immunisation (19). 153
We observed no differences in antibody responses to any antigen, including PPD, between the BCG 154 vaccinated individuals and naïve controls at the 3 week time point (Figure 2a ). These results 155 mirrored non-significant differences observed between the two groups before BCG vaccination 156 ( Figure 2b ). These findings indicate that BCG vaccination may not be able to boost antibody 157 responses to heterologous pathogens, or at least not within the 3 week time frame. 158 159
Avidity of tetanus toxoid and measles virus-specific
160 antibodies is increased in APTB 161 We determined whether the observed increases in antibody responses to unrelated recall antigens in 162 M.tb infected individuals was accompanied by changes in their avidity or overall binding strength. An 163 increase in avidity could point to MBCs being the source of heterologous pathogen antigen-specific 164 antibodies because these cells would have already undergone affinity maturation. To this end, the 165 avidity of antibodies against tetanus toxoid (TT) and measles virus haemagglutinin (MVHA) antigens 166 were investigated using SPR. Due to limitations in sample volumes, only 88 of the 237 KTB study 167 participants' samples were tested. 168
Initial crude comparisons showed marginal evidence of a difference in dissociation rate (the measure 169 of avidity) in TT-specific antibodies across the three groups ( Figure 3 ). For the final analysis, linear 170 regression was used to evaluate associations between M.tb infection state and antibody avidity using 171 the uninfected controls as the baseline comparison group while adjusting for the effects of age, 172 gender, HIV infection status and socioeconomic status ( Table 2) . APTB and LTBI were associated 173 with the presence of TT-specific antibodies of a slower dissociation rate, a sign of higher avidity. 174
Having APTB was also associated with MVHA specific antibodies of a slower dissociation rate. 175
These results lend credence to the hypothesis that the increased antibody responses against 176 heterologous pathogen recall antigens observed in M.tb infection arise from antigen-specific MBCs. 177 In order to explore the possibility that M.tb infection may be driving differentiation of MBCs 186 specific to unrelated recall antigens into plasmablasts in our study participants, we examined the 187 frequency of TT-specific MBCs and plasmablasts in 48 APTB cases and 115 healthy donors using B 188 cell ELISPOT assays. 189
We had limited PBMC numbers from the APTB cases and so MBC frequencies were ascertained in 190 18 of the APTB cases while plasmablast frequencies were evaluated in the rest (n=30). The ratio of 191 the median frequencies of TT-specific plasmablasts to MBC in the APTB cases was 7:1 (8.75:1.25; 192 Efforts to determine TT-specific plasmablast to MBC ratio in the healthy donors for comparison 197 were not possible because TT-specific plasmablasts were not readily detected during preliminary 198 analyses. However, high frequencies of TT-specific MBC were detected in these individuals at levels 199 above those seen in the APTB cases ( Supplementary Fig. 2 immunity to heterologous pathogens that individuals may have been previously exposed to, through 207 infection or immunisation, and shows that vaccination with the related bacterium, Mycobacterium bovis 208 BCG does not have a similar effect. The increase in the levels and avidity of these antibodies in M.tb 209 infected individuals means that MBCs are their likely source. Additionally, the abundance of TT-210 specific plasmablasts relative to TT-specific MBCs in active TB disease provides evidence to support 211 the hypothesis that M.tb infection drives polyclonal activation of MBCs generated against unrelated 212 recall antigens. If this property can be exploited, it may lead to the production of immunological 213 therapies than can be used to boost serological memory to a wide variety of infections, particularly in 214 people with waning immunity such as the elderly. 215
The fact that the increase in antibody responses to heterologous pathogens was most evident in 216 APTB disease may mean that this non-specific effect is most pronounced in a milieu of actively 217 replicating tubercle bacilli. Indeed, previous research has shown that active TB disease is associated 218 with increases in cytomegalovirus-specific antibodies (21, 22) , however, these studies attributed the 219 rise in antibodies to concurrent infection with CMV rather than as a marker of serological memory. 220
A study by de Paus and colleagues (2013) observed higher levels of influenza-specific antibodies in 221 individuals with TB and recognized that in addition to concurrent infection there was a possibility 222 that these may have arisen as a result of mycobacterial driven non-specific increases in antibodies. 223
The marginal increases in TT-specific antibody levels in LTBI and the statistically significant 224 increase in SPR determined TT-specific antibody avidity in LTBI indicate that LTBI, like APTB, 225 may boost antibody responses to heterologous pathogens, albeit to a lesser extent. It is now 226 recognised that LTBI is not a fully quiescent state of infection but may at times be associated with 227 subclinical disease arising from reactivation of M.tb (24, 25) . Mycobacterial growth in this state may 228 drive the observed non-specific increases in antibody responses. 229
The observation that BCG vaccination did not have a similar effect may mean that proteins unique 230 to M.tb may mediate the increase in antibody responses to these heterologous pathogens observed in 231 APTB. Alternatively, this may point to the effect of BCG mycobacterial load at the site of 232 inoculation, which may fall short of the M.tb bacillary load observed in the lungs during active TB 233 disease. The lack of significant stimulation of anti-mycobacterial antibodies in the BCG vaccinated 234 recipients, in contrast to the more than 3-fold rise in the same in the APTB cases (Table 1) supports 235 this reasoning. The lack of antibody response may also simply be due to the timing after vaccination. 236 A later time point may have allowed the accrual of BCG-specific antibodies; we were not able to 237 assess this in our study. 238 Antibody responses to recall antigens from heterologous pathogens were increased in both level and 239 avidity in M.tb infection. This gave further evidence that the source of these antibodies are MBCs 240 because these cells would have already undergone affinity maturation, and as a consequence produce 241 antibodies of high avidity. A study by Zimmerman and colleagues (2016) This study has a few limitations. We assumed that the antibody responses detected against the 266 chosen heterologous pathogen antigens in our study participants arose as a result of past exposure 267 via infection or vaccination. However, recent or current exposure to these multiple pathogens, 268 although unlikely, was possible. 269
On the whole, these data show a hitherto unknown role for M.tb in the maintenance of serological 270 memory generated against past infections and vaccinations. It has been hypothesised that exposure 271 to infections in later life could help maintain antibody responses to a broad set of pathogens in the 272 absence of their specific antigens. This process is proposed to be due to polyclonal stimulation of 273 antigen MBCs (11, 30) and the data presented here would support this. However, further 274 experimentation is required to confirm the mechanism involved and identify the specific M.tb 275 antigens mediating this process. This research may aid in the development of therapeutics to boost 276 antibody immunity to heterologous pathogens. It is envisaged that this treatment could be useful in 277 ageing populations in whom antibody responses to specific infections are known to wane. The 278 advantage of this approach is that instead of boosting these individuals with multiple vaccine 279 antigens, a single treatment could be provided to increase serological immunity to several pathogens 280 all at once. 281 received treatment for less than 4 weeks. APTB was ascertained using acid fast bacilli sputum 290 microscopy. Individuals with LTBI were identified from among healthy HHCs using the tuberculin 291 skin test and QuantiFERON-TB Gold in-tube (QFT-GIT) test. The HHCs that tested positive on 292 both these tests were classified as having LTBI whereas those that tested negative on both tests were 293 classified as uninfected controls. A total of 68 uninfected controls, 62 individuals with LTBI and 107 294 APTB cases were included in our study. QuantiFERON-TB Gold in-Tube (QFT-GIT) nil 295 supernatant samples from these individuals were used for the antibody analyses. The choice of 296 QFT-GIT supernatants was because serum samples were not available for all the individuals studied. 297
Materials and Methods
We have previously shown that there are no differences between antibody concentrations obtained 298 from assaying serum and those from assaying QFT-GIT supernatants (34). 299 Stored plasma samples from adolescents participating in a UK based prospective study on BCG 300 responses were used to determine whether BCG vaccination was associated with non-specific 301 increases in antibody responses to heterologous pathogen recall antigens. These individuals were 302 part of a UK government programme on BCG vaccination in schools in the year 2005 and were 303 invited to take part in a research study that sought to identify immune responses involved in BCG 304 mediated protection against TB. The adolescents studied included 12 subjects who were given BCG 305 and then followed up after three weeks as well as 13 age-matched controls who did not receive BCG 306 and were followed up for the same period of time. All the subjects had no previous BCG scar (a sign 307 of earlier BCG vaccination) and had a negative TST prior to immunisation (13). Samples obtained 308 from these individuals before BCG vaccination and at the 3 week timepoint were analysed. This 309 cohort was chosen because it gave us the unique opportunity to compare BCG vaccinated and 310 unvaccinated controls, something which could not be easily done in Ugandan cohorts considering 311 BCG is part of the immunisation schedule in the country (19) . 312
In order to investigate MBC polyclonal activation as a possible cause of the elevated antibody 313 responses to heterologous pathogens in people with TB, cryopreserved PBMCs from 48 APTB 314 cases from the TB household contact study and fresh PBMCs from 115 healthy donor controls were 315 analysed to determine the effect of an active TB infection on the frequencies of tetanus toxoid-316 specific plasmablasts and MBCs. The healthy donors were recruited from a voluntary HIV 317 counselling and testing clinic at the Uganda Virus Research Institute. They were all HIV negative, 318 aged 18-55 years and found to be healthy by a clinician. 319
These studies were all exploratory and the sample size was determined by the availability of 320 sufficient samples and reagents for laboratory analyses. 321 The plates were thawed at 37 °C in preparation for the assay and washed three times with PBST. A 1 359 in 100 dilution of the sample or controls was prepared and then 100 µl was added per well in 360 duplicate. Each plate had 3 positive and 2 negative control samples for quality control. After an 361 incubation of 90 min at 37 °C, the wells were washed five times and incubated with 100 µl/well goat 362 anti-human IgG conjugated with alkaline phosphatase (Roche Diagnostics) diluted 1 in 5,000 for 30 363 min at 37 °C. The plates were washed five times and enzyme activity detected by incubation with 364 100 µl/well 1-step p-nitrophenyl phosphate substrate solution (Thermo Scientific Pierce, USA) for 365 30 min at room temperature in the dark. This reaction was stopped by the addition of 50 µl/well of 366 3 N NaOH and then the plates were read at a wavelength of 405 nm. 367 368
Ethics Statement
CMV antibody ELISA
369
Platelia™ CMV IgG ELISA was used to measure CMV-specific antibodies as per the 370 manufacturer's instructions (3). Briefly, diluted samples, standards of known anti-CMV antibody 371 concentration and controls were added to microtitre plates pre-coated with CMV antigens. The 372 plates were incubated with the samples at 37°C for 45 min and thereafter washed with buffer. A 373 conjugate composed of horseradish peroxidase enzyme bound onto anti-human IgG monoclonal 374 antibody was then added to each well and incubated for 45 min at 37°C. The plates were washed 375 and an enzyme substrate was added to each well followed by a 15-min incubation at room 376 temperature. After this, a stop solution was added and the OD read at 450 nm wavelength. 377
Total IgG antibody ELISA
378
Human IgG total Ready-SET-Go (Affymetrix ebioscience) was used to measure total IgG following 379 the manufacturer's instructions (35). In the procedure, Immulon 4 HBX microtiter plates were 380 coated with 100 µl/well purified anti-human IgG monoclonal antibody overnight at 4 ºC. The plates 381 were then washed twice with wash buffer and incubated with 250 µl/well blocking buffer for 2 h at 382 room temperature. The plates were washed twice and eight, recombinant human IgG controls were 383 prepared and the samples were diluted 1 in 100,000. A volume of 100 µl/well of the prepared 384 standards and samples was added to the plates and then incubated for 2 h at room temperature. In 385 the next step, the plates were washed four times and incubated with 100 µl/well HRP-conjugated 386 anti-human IgG monoclonal detection antibody for 1 h at room temperature. The plates were 387 washed four times and incubated with 100 µl/well tetramethylbenzidine (TMB) substrate solution 388
for 15 min at room temperature in the dark. After this duration, the reaction was stopped by 389 addition of 100 µl/well stop solution and the plates read at 450 nm wavelength. 
B cell ELISPOT
407
We used in-house in vitro and ex-vivo B cell ELISPOTS to determine the frequency of TT-specific 408 plasmablasts and MBCs respectively in APTB cases and healthy donors following methods 409 described by Sebina et al. (36, 37) . Cryopreserved PBMCs were thawed, resuspended in RPMI (Gibco 410 by Life Technologies) containing 10% (v/v) fetal bovine serum, 2 mM L-glutamine (both from 411 Sigma-Aldrich, UK) and 1x penicillin-streptomycin (Invitrogen). The cells were then rested for 4-6 412 hours at 37°C and 5% CO2. 413 In the in vitro ELISPOT, PBMCs at a cell density of 1x10 6 cells/ml were stimulated with a mixture of 414 25 ng/ml human IL-10 (R&D Systems, UK), 0.5 µg/ml of pokeweed mitogen (PWM), 6 µg/ml of 415 CpG oligodeoxynucleotide, 1.2 mg/ml Staphylococcus aureus Cowan, 50 µM ß-mercaptoethanol at 416 37°C and 5% CO2 for six days. Approximately 4x10 5 of the cultured cells were then transferred to 417 each well of 96-well filter (Merck Milipore) pre-coated with 2 µg/ml TT in 1x PBS or only 1xPBS. 418
The plates were sealed and incubated for 6 hours at 37°C and 5% CO2 after which biotin-SP 419 conjugated affinipure fragment donkey antihuman IgG (Jackson ImmunoResearch) was added to 420 the plate wells to aid in the detection of anti-TT specific antibody secreting cells. After overnight 421 incubation at 4°C, streptavidin-AKP (BD biosciences) was added and the plates incubated for an 422 hour at room temperature followed by AP-conjugate substrate (Bio-rad, USA) to develop the spots. 423
After 10 minutes the plate wells were rinsed with water and left to dry before they were read using 424 an AID ELISPOT reader (AID Diagnostika, Germany). The number of MBCs was then expressed 425 as the total number of spots per million cells. 426
The ex vivo ELISPOT involved the direct transfer of the rested PBMCs to the 96-well filter plates at 427 a cell density of 4x10 5 cells/well. All the subsequent steps were similar to those described for the in 428 vitro ELISPOT. 429 
Statistical Analysis
